Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulsan
Clinical trial register · South Korea

Clinical Trials in Ulsan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline8 Eli Lilly and Company7 Regeneron Pharmaceuticals6 Ulsan University Hospital5 Hoffmann-La Roche5
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Ulsan

81 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Intuitive Surgical
Observational
151
Goyang-si, Daejeon, Seoul, Ulsan
2027-01
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Ulsan, Goyang-si, Namdong-gu, Busan, Seoul, Bucheon-si, Goyang, Iksan
2026-12-16
Recruiting
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
NCT07539324Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Genoss Co., Ltd.
Not applicable
892
Ulsan
2026-09-28
Not yet open
LucasBio
Phase 1/2
42
Seoul, Daegu, Goyang-si, Hwasun, Ulsan
2026-09-01
Recruiting
Eli Lilly and Company
Phase 2
606
Bupyeong-gu, Dongjak-gu, Gyeongsan-si, Seoul, Ulsan, Wŏnju
2026-08-07
Recruiting
Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases
NCT07678606Cardiovascular Disease, Cardiac Magnetic Resonance Imaging, Neoplasm
Ulsan University Hospital
Observational
1,000
Ulsan
2026-07-01
Recruiting
GlaxoSmithKline
Phase 2
200
Seoul, Ulsan
2026-04-15
Not yet open
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
NCT07398001Percutaneous Coronary Intervention, Antiplatelet Therapy, Drug-coated Balloon
Ulsan University Hospital
Not applicable
1,042
Ansan, Chuncheon, Pusan, Seoul, Ulsan
2026-02-12
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Hwasun, Seoul, Ulsan
2026-01-02
Recruiting
NOBO Medicine
Phase 1
9
Hwasun, Seongnam, Seoul, Ulsan
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, Ulsan
2025-12-01
Recruiting
AstraZeneca
Phase 2
435
Anyang-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Ulsan
2025-11-06
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Daejeon, Daegu, Busan-si, Pusan, Ulsan, Namdong, Hwasun, Seoul
2025-09-26
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan
2025-09-02
Recruiting
Chonnam National University Hospital
Not applicable
256
Busan, Daegu, Gwangju, Jeonju, Seoul, Ulsan
2025-08-18
Recruiting
GlaxoSmithKline
Phase 3
420
Changwon, Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Seongnam-si Gyeonggi-do, Seoul, Suwon Gyeonggi-do, Ulsan
2025-08-11
Recruiting
Amgen
Phase 3
12,800
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Gyeonggi-do, Seoul, Ulsan, Wonju-si, Gangwon-do
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Goyang, Incheon, Seongnam-si, Seoul, Suwon, Ulsan
2025-07-24
Recruiting
Takeda
Observational
9
Seoul, Ulsan
2025-07-22
Active, closed
Aligos Therapeutics
Phase 2
200
Ansan, Busan, Seoul, Ulsan, Yangsan
2025-07-15
Recruiting
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
NCT07405931Early Gastric Cancer, Advanced Gastric Cancer, Early Lung Cancer, Advanced Lung Cancer
Ulsan University Hospital
Not applicable
414
Busan, Goyang, Incheon, Jinju, Ulsan
2025-07-09
Recruiting
Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea
NCT07057648Lung Nodules, Peripheral Lung Lesions, Pulmonary Nodules, Lung Cancers
Ulsan University Hospital
Observational
100
Ulsan
2025-07-09
Recruiting
Medipixel XA-Assisted PCI in Coronary Artery Disease
NCT06985693Percutaneous Coronary Intervention (PCI), Coronary Arterial Disease (CAD)
CHA University
Not applicable
830
Gwangmyeong, Seongnam-si, Daegu, Gwangju, Jeonju, Ulsan
2025-05-15
Recruiting
Gilead Sciences
Phase 3
695
Changwon-Si, Gwangju, Seongbuk-Gu, Seongnam, Seoul, Suwon, Ulsan
2025-04-04
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Recruiting
Shin Poong Pharmaceutical Co. Ltd.
Phase 3
852
Busan, Ulsan
2025-02-14
Recruiting
GlaxoSmithKline
Phase 3
520
Hwasun, Jeonju, Seoul, Ulsan
2024-12-16
Recruiting
NOBO Medicine
Phase 2
33
Busan, Hwasun, Ilsan, Seongnam, Seoul, Ulsan
2024-11-25
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Seoul, Ulsan, Busan
2024-11-15
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Cheongju-si, Seongnam-si, Incheon, Seoul, Busan, Daegu, Gyeonggi-do, Ulsan
2024-09-27
Active, closed
Genmab
Phase 3
379
Busan, Seongnam-si, Daegu, Jeonju, Hwasun-gun, Seoul, Ulsan
2024-08-13
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Gyeonggi-do, Suwon, Hwasun, Incheon, Seoul, Ulsan
2024-07-16
By invitation
Genoss Co., Ltd.
Observational
3,000
Ulsan
2024-06-27
Active, closed
AbbVie
Phase 3
421
Seoul, Ulsan
2024-05-19
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Busan, Daegu, Donggu, Goyang, Seoul, Uijeongbu-si, Ulsan
2024-03-13
Recruiting
AstraZeneca
Phase 3
5,250
Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan
2024-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Busan, Jeollanam-do, Seoul, Ulsan
2024-01-22
Active, closed
DualityBio Inc.
Phase 3
541
Busan, Wŏnju, Seongnam-si, Seoul, Suwon, Incheon, Cheonan, Ulsan
2024-01-18
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Suwon, Jeonju, Incheon, Busan, Daegu, Seoul, Ulsan
2023-12-28
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Daegu, Seongnam-si, Seoul, Ulsan
2023-12-11
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
Busan, Ulsan, Suwon, Jinju, Jeonju, Daegu, Sinchon-dong, Songpa-dong
2023-10-04
Active, closed
Hoffmann-La Roche
Phase 3
687
Goyang-si, Gyeonggi-do, Jeollanam-do, Seoul, Ulsan
2023-09-14
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-08-08
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Incheon, Suwon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-06-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Busan, Goyang-si, Seongnam-si, Gyeonggi-do, Seoul, Ulsan
2023-06-22
Active, closed
Amgen
Phase 3
509
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Incheon, Jinju, Seongnam-si, Gyeonggi-do, Seoul, Ulsan
2023-05-31
Active, closed
Genmab
Phase 3
900
Busan, Seongnam-si, Daegu, Jeonju, Seoul, Ulsan
2023-02-08
Recruiting
Ulsan University Hospital
Observational
510,000
Ulsan
2023-01-01
Active, closed
Amgen
Phase 3
7,297
Busan, Gwangju, Incheon, Seongnam-si, Gyeonggi-do, Seoul, Ulsan, Wonju-si, Gangwon-do
2022-12-14
Active, closed
Celcuity Inc
Phase 3
701
Seoul, Soeul, Ulsan
2022-12-08
Active, closed
GlaxoSmithKline
Phase 1/2
14
Seoul, Ulsan
2022-08-31
Recruiting
Yuhan Corporation
Phase 1/2
147
Seongnam-si, Suwon, Jinju, Cheongju-si, Incheon, Seoul, Ulsan
2022-08-26
Active, closed
Daewoong Pharmaceutical Co. LTD.
Phase 2
102
Busan, Bucheon-si, Goyang-si, Hwaseong-si, Seoul, Ulsan
2022-07-29
Active, closed
GlaxoSmithKline
Phase 1/2
20
Seoul, Ulsan
2022-07-19
Active, closed
Incyte Corporation
Phase 1/2
53
Suwon, Busan, Daegu, Incheon, Jeonju, Seoul, Ulsan
2022-07-19
Active, closed
Hoffmann-La Roche
Phase 3
660
Cheongju-si, Daegu, Gyeongsangnam-do, Seongnam-si, Seoul, Ulsan
2021-11-18
Active, closed
Asan Medical Center
Phase 4
600
Daegu, Seoul, Ulsan
2021-08-23
Active, closed
GlaxoSmithKline
Phase 1/2
30
Seoul, Ulsan
2021-07-29
Active, closed
da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures
NCT04403022Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors
Intuitive Surgical
Not applicable
60
Ulsan, Seoul
2021-06-03
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
Genmab
Phase 3
483
Busan, Daegu, Geumam, Seoul, Ulsan
2021-01-13
Active, closed
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
NCT04414163Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
DrugDanburstotug
ImmuneOncia Therapeutics Inc.
Phase 2
23
Gwangju, Seoul, Ulsan
2020-10-27
Active, closed
Hoffmann-La Roche
Phase 3
992
Cheongju-si, Daegu, Gyeonggi-do, Incheon, Seoul, Ulsan
2020-10-09
Active, closed
Hoffmann-La Roche
Phase 3
190
Seoul, Ulsan
2020-09-30
Active, closed
Baxalta now part of Shire
Observational
207
Seoul, Ulsan
2020-07-09
Active, closed
GlaxoSmithKline
Phase 1/2
106
Incheon, Seoul, Ulsan
2020-06-08
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,872
Seoul, Ulsan
2020-05-29
Active, closed
GlaxoSmithKline
Phase 3
494
Pusan, Ulsan
2020-05-07
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Ulsan, Gyeonggi-do, Busan, Seoul
2019-11-13
Active, closed
Young-Suk Lim
Phase 4
780
Daegu, Seongnam, Seoul, Ulsan
2019-02-18
Active, closed
AbbVie
Phase 3
265
Incheon, Seoul, Ulsan
2018-10-22
Active, closed
AstraZeneca
Phase 3
1,186
Busan, Chungcheongbuk-do, Daegu, Incheon, Seongnam-si, Seoul, Ulsan
2017-06-01
Active, closed
Pfizer
Phase 3
296
Suwon, Seoul, Ulsan
2017-04-27
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Daejeon, Gwangju, Jeonju, Seoul, Suwon, Ulsan
2016-12
Recruiting
Samsung Medical Center
Observational
797
Incheon, Seongnam, Seoul, Taebuk, Ulsan
2016-06-10
Active, closed
Eli Lilly and Company
Phase 3
545
Cheongju-si, Seongnam, Suwon, Jinju, Seoul, Ulsan
2015-05-06
Active, closed
Eli Lilly and Company
Phase 3
493
Incheon, Goyang-si, Seongnam, Seoul, Daegu, Ulsan
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
Goyang-si, Incheon, Seoul, Seowon-Gu, Suwon, Ulsan
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Recruiting
Drug-Eluting Balloon Registry in Routine Clinical Practice
NCT02038660Coronary Artery Disease, Angioplasty, Balloon
Seung-Jung Park
Observational
1,500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seoul, Ulsan
2014-01
Recruiting
Ulsan Medical Center
Observational
10,000
Ulsan
2011-04-22
Rows per page Showing 1–81 of 81
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/ulsan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 81 of those studies with a site in Ulsan.

How many clinical trials are recruiting in Ulsan?

33 of the 81 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 4 have not yet opened recruitment, 43 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulsan), 81 studies
PhaseStudiesRecruitingShare
Phase 3391448.1%
Observational12914.8%
Phase 210412.3%
Not applicable849.9%
Phase 1/2718.6%
Phase 2/3202.5%
Phase 4202.5%
Phase 1111.2%

Most active sponsors

Lead sponsors with the most studies (Ulsan)
Lead sponsorStudiesRecruiting
GlaxoSmithKline83
Eli Lilly and Company73
Regeneron Pharmaceuticals62
Hoffmann-La Roche50
Ulsan University Hospital54
Amgen31
AstraZeneca32
Genmab30
AbbVie20
Bristol-Myers Squibb20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.